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TO THE EDITOR
Genomic abnormalities are emerging as crucial prognostic parameters in multiple myeloma (MM). Deletion of chromosome arm 13q (13qÀ) is present in 40-60% of tumors and has been recognized as an independent predictor of a dismal prognosis. Using chromosome banding analysis, only about a third of myelomas exhibit an abnormal karyotype. Moreover, evaluable metaphases are missing in up to one-fourth of cases, as shown in large cytogenetic studies. By molecular cytogenetic techniques, for example, comparative genomic hybridization (CGH) or fluorescence in situ hybridization (FISH), genomic changes can be identified in more than 90% of plasma cells primary tumors. While banding analyses fail to identify certain chromosomal aberrations, for example, small deletions or translocations with breakpoints located near the telomere, such abnormalities can be reliably detected by FISH. Therefore, FISH has become the most widely used tool for molecular diagnostics in MM today.
Analogous to the acute and chronic leukemias, genomic aberrations most likely represent the biological basis of the clinical heterogeneity, that is also characteristic for MM. While our understanding of the implication of various translocations in MM has gradually increased, 1,2 little is known about chromosomal imbalances in this disease. Even the exact incidence of most chromosomal gains and losses in MM are unknown to date. To address this issue, we developed a comprehensive, disease-specific DNA probe set for the evaluation of chromosomal imbalances in plasma cell malignancies and determined the incidence of genomic gains and losses in a large prospective series of myelomas.
From August 1998 to November 2002, bone marrow aspirates from 357 consecutive patients diagnosed with MM were obtained for molecular cytogenetic analysis during routine diagnostic procedures. Of the 357 patients, 290 (81%) were entered on two national treatment trials and were newly diagnosed. The remaining patients had previous therapy. Informed consent was obtained from all patients. There were 141 female (39.5%) and 216 male patients (60.5%). Almost all patients had advanced stage myeloma (Salmon-Durie stage: II -21%, III -76%; others: 3%). At the time of specimen collection, the ages of the patients ranged from 28 to 76 years (median, 56 years). Mononuclear cells were separated by density-gradient centrifugation and cytospin preparations were performed. The quality of the cells and the proportion of tumor cells in the bone marrow samples were assessed by morphology on a MayGrü nwaldFGiemsa-stained cytospin preparation. Plasma cell enrichment using immunomagnetic beads directed against the CD138 antigen was performed in 29 specimens with a low tumor cell fraction. Tumor samples of insufficient cell quality (eg due to prolonged shipment to our central reference laboratory) or with o1% tumor cells after positive selection of plasma cells were not analyzed. Depending on the tumor cell light chain type, overnight incubation with the respective AMCA-labeled light chain antibody was used for the detection of myeloma cells during fluorescence microscopy. At least 100 AMCA-positive plasma cells were evaluated.
Based on our CGH study that resulted in the identification of genomic regions commonly gained or deleted in MM, 3 a comprehensive set of DNA clones for the detection of the most frequent chromosomal imbalances was assorted. To achieve high accuracy in diagnosis, probes were selected from the critical regions of these imbalances as delineated by CGH. This probe panel comprised probes mapping to chromosome bands 1p22, 1q21, 6q21, 8p11, 9q34, and 11q25. DNA clones from chromosome bands 13q14 (locus D13S272), 17p13 (p53), and 22q11 were added to this panel, as deletions involving these genomic loci have been previously reported to provide prognostic information in MM.
The following DNA clones were used: RPCI-11 71-L-20 (1q21.2), RPCI-11 210-F-08 (1q43), RPCI-11 284-J-03 (8p11.3), RPCI-11 40-A-07 (9q34.2), and RPCI-11 17-M-17 (11q25; all purchased from the RPCI-11 human male BAC library, http:// www.chori.org/bacpac). A P1-phage artificial chromosome (PAC) clone mapping to chromosome band 22q11 (RPCIP 704 L11257) was received from the Resource Center/Primary Database (RZPD), Berlin, Germany (http://www.rzpd.de). In addition, PAC clones derived from the following YAC clones were used: YAC 224i04 (mapping to band 1p22), YAC 963d06 (6q21), YAC 755b11 (11q22.3-q23.1), YAC 272/3 (13q14), and YAC p53 (17p13). 4 An aberration was diagnosed, if the proportion of cells with one (deletion) or three/four (trisomy/ tetrasomy) hybridization signals exceeded the maximum cutoff value determined for four DNA probes on bone marrow specimen from healthy donors (mean percentage of abnormal cells73 s.d.: 14% for deletions, 16% for trisomies/tetrasomies). Figure 1 summarizes the data with the DNA probe set. Genomic losses and gains with an incidence greater than 10% were identified in five and three chromosomal bands, respectively.
Among the chromosomal losses, a monoallelic deletion of chromosome band 13q14 (locus D13S272) was identified in 43.0% (148 of 344 tumors) and therefore was by far the most frequent genomic loss in our series. This is in accordance with other recently published FISH analyses.
1,2 The proportion of 13q-deleted plasma cells ranged from 27 to 99% (median, 82%). No biallelic 13q deletion was found. Six tumors exhibited 13q gains (1.7%). Deletions involving chromosome bands 1p22, 22q11, 6q21, and 8p11 were found at a lower frequency (13.8, 13.1, 12.3, and 12.3%, respectively). Deletion of chromosome band 17p13 was identified at very low frequency (16 of 330 tumors, 4.8%) in our series.
Among the chromosomal gains, trisomy of chromosome arm 9q ( þ 9q34) was identified in 111 of 235 tumors (47.2%) and therefore was the most frequent chromosomal gain in the present series. Substantial interphase cytogenetic studies referring to the frequency of 9q abnormalities in MM are lacking. In conventional chromosome banding and CGH analyses, the incidence of þ 9/ þ 9q ranged from 6 to 30% and from 12 to 58%, respectively. A FISH survey applying a panel of centromeric probes revealed a very high incidence of þ 9 (82%) in a small series of samples (n ¼ 55). 5 In our study, a large series of samples were analyzed using a probe mapping to the critical region of this abnormality that was previously delineated by CGH. Thus, our data provide a reliable basis for a correlation of this aberration with patient characteristics and outcome.
Trisomy of chromosome arm 11q ( þ 11q) was detectable in 109 of 291 myeloma tumors (37.4%) and thus was the second most prevalent chromosomal gain in our study. With an incidence ranging from 2 to 12%, trisomies of chromosome 11 ( þ 11) were reported as recurrent aberrations in cytogenetic studies. In one large chromosome banding analysis, 6 þ 11q was found in only two of 345 cases (0.5%). Using CGH, chromosome 11 gains were present in 23-62% of cases. In all CGH studies, a commonly gained chromosomal segment on the long arm of chromosome 11 was identified.
3 Only few FISH data relating to chromosome 11 extra copies were published so far. Two studies revealed þ 11 in 33 and 38% of cases, respectively, but these studies had limitations of either using DNA probes outside the putative critical region or with respect to the small number of patients analyzed. 7, 8 Analogous to the 9q aberration, we applied a DNA probe from the critically gained chromosomal segment on a large number of tumors, thus providing reliable data with respect to the incidence of this abnormality.
Trisomy of chromosome arm 1q ( þ 1q) was detected in 65 of 205 myelomas (31.7%) and therefore was the third most common chromosomal gain in our series. FISH data on the frequency of 1q imbalances in MM are scarce, while recurrent gains on chromosome 1q were found in up to 58% of tumors using CGH.
Present in 30-50% of myeloma tumors, trisomies of chromosome arms 1q, 9q, and 11q are by far the most common genomic gains in MM, which points to an important role of these genomic aberrations in MM pathogenesis. Current analyses focus on: (1) the characterization of the consensus regions as well as the identification of candidate genes within the critical genomic segments and (2) the prospective evaluation of the prognostic significance of these aberrations in multicenter treatment trials.
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Figure 1
Incidences (in %) of chromosomal imbalances in MM. Bars to the right: trisomies (white), tetrasomies (gray). Bars to the left (black): deletions. Owing to preliminary FISH mapping data (not shown) and evolving CGH data, two initially used PAC probes (mapping to 1q43 and 11q22.3-q23.1) were exchanged with probes for bands 1q21 and 11q25, respectively, to improve the sensitivity of our DNA probe set. 
EBV-related lymphoproliferative disorders in immunocompetent patients
Leukemia ( The new WHO classification of lymphomas recognizes four clinical settings of immunodeficiency associated with an increased incidence of lymphoma and other lymphoproliferative disorders: (1) primary immune disorders; (2) HIV infection; (3) iatrogenic immunosuppression after solid organ or bone marrow transplantation; and (4) iatrogenic immunosuppression due to methotrexate treatment. 1 We describe three patients with an EBV-related lymphoproliferative disorder (LPD) without known underlying primary or secondary immune disorder, and suggest that EBV-related LPDs may occur more frequently than expected.
The first patient was a 34-year-old woman from Turkish ancestry. Her medical history revealed an autoimmune hemolytic anemia during her pregnancies in 1995 and 1997. In April 2002, she presented with fever, malaise and weight loss. Physical examination revealed a hepatosplenomegaly without lymphadenopathy. Biochemical analysis of the blood showed a pancytopenia with normal differential WBC and a markedly elevated LDH of 1348 U/l (normal value o450 U/l). ANA and ANCA were negative, EBV-IgG was 64 reciprocals of dilution, EBV-IgM was negative, and HIV was negative. The qualitative PCR for EBV performed on the whole blood was positive. CT scan showed pleural effusion, hepatosplenomegaly, and ascites. Bone marrow biopsy revealed interstitial infiltration with large polymorphic B-lymphocytes, partly with striking plasmacytic differentiation, classified as diffuse large B-cell lymphoma (Figure 1a) . Immunophenotyping with CD45 and CD20 were positive, CD79a and CD30 were heterogeneously positive. EBER (EBV-encoded small nonpolyadenylated RNAs) in situ hybridization was performed because of the unusual histology, and proved to be positive in the atypical cells. We were not able to assess reliable immunoglobulin expression in this decalcified paraffin-embedded material. The patient received eight courses of CHOP in combination with four courses of Rituximab (anti-CD20 antibodies). Her constitutional symptoms disappeared. Bone marrow histology and qualitative PCR for EBV became negative; however, the spleen remained slightly enlarged (diameter 13 cm). At 6 months after completion of treatment, this response is still ongoing.
The second patient was a 57-year-old woman, with a history of hypertension and diabetes mellitus type II. She presented with multiple enlarged lymph nodes in the neck region. She had no constitutional symptoms. Peripheral blood counts and LDH were normal. EBV-IgG was 256 reciprocals of dilution, EBV-IgM and HIV were negative. Bone marrow biopsy was negative. Lymph node biopsy showed an EBV-positive very polymorphic diffuse large B-cell lymphoma with similar histology and phenotype as the first patient, again with an unusual plasmacytic differentiation. Immunofluorescence for immunoglobulin was negative. She showed a complete response after six courses of conventional polychemotherapy without anti-CD20 antibodies. At this time, radiotherapy is given for the initially bulky localization in the neck.
The third patient was a 69-year-old woman of Chinese ancestry. Apart from diabetes mellitus type II with macrovascular complications, she had no medical history. She presented with fever, diarrhea, abdominal pain and weight loss. Biochemical analysis of the blood showed an autoimmune hemolytic anemia due to cold agglutinins IgM anti-I, with an elevated LDH of 1034 U/l. Serologic analysis showed that she was seronegative for HIV and HTLV-1, and also ANA and ANCA were negative. The IgG anti-EBV titer was 32 reciprocals of dilution; IgM anti-EBV was negative. Qualitative PCR analysis of EBV in peripheral blood was negative. A bone marrow biopsy revealed no abnormalities. Colonoscopy revealed multiple ulcerating lesions in the sigmoid colon (Figure 1b) . Pathologic analysis of biopsies from one of these lesions showed large atypical lymphoid cells with strong plasma cell differentiation (Figure 1c ). The cells were positive for CD79A, but only partially for CD20, and were negative for CD30 and LMP-1 (EBV-encoded latent membrane protein). There was a striking polyclonality for kappa and lambda. Many of the atypical cells were positive for EBER in situ hybridization (Figure 1d ). During her hospital stay, she developed upper gastrointestinal bleeding complicated by myocardial infarction. Due to her bad clinical condition, she was no candidate for intensive chemotherapy. She died 6 weeks after diagnosis.
In younger patients, such as the first patient, EBV-associated LPDs are associated with a variety of primary immunodeficient states such as congenital immunodeficiency and autoimmune lymphoproliferative syndrome.
1,2 In middle-aged and elderly patients, such as the second and third patients, respectively,
